Oncology (all articles)
M-A: Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer.
22 Apr, 2022 | 09:26h | UTC
State of the Art Review: Novel treatments in B cell non-Hodgkin’s lymphomas.
22 Apr, 2022 | 09:24h | UTCNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Commentary on Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
ASCO Guideline Update: biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer.
20 Apr, 2022 | 09:47h | UTC
M-A: Association of immune checkpoint inhibitors with neurologic adverse events.
20 Apr, 2022 | 09:34h | UTCInvited Commentary: Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now? – JAMA Network Open
Related:
Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review – Neurology (link to abstract – $ for full-text)
Commentary on Twitter
Meta-analysis of 39 RCTs found immune checkpoint inhibitors have lower risk of neurological adverse effects compared to cytotoxic chemotherapy, but higher than placebo, across a range of malignancies. https://t.co/02GhICcu5H
— JAMA Network Open (@JAMANetworkOpen) April 19, 2022
RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.
20 Apr, 2022 | 09:28h | UTC
Commentary on Twitter
Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu
— The BMJ (@bmj_latest) April 19, 2022
Development and validation of machine learning models for predicting occult nodal metastasis in early-stage oral cavity squamous cell carcinoma.
20 Apr, 2022 | 09:14h | UTC
Commentary on Twitter
In this diagnostic modeling study, #MachineLearning models built with multi-institutional data showed potential to reduce morbidity from elective neck dissections with similar cancer outcomes in patients with early-stage oral cavity squamous cell carcinoma https://t.co/aRktgc0ms6
— JAMA Network Open (@JAMANetworkOpen) April 13, 2022
RCT: Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma.
20 Apr, 2022 | 09:09h | UTCFuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Opinion | Low-grade prostate cancer (Gleason score 6): time to stop calling it cancer.
19 Apr, 2022 | 02:29h | UTCLow-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Commentary: Doctors suggest new names for low-grade prostate cancer – Associated Press
AI reduces miss rate of precancerous polyps in colorectal cancer screening.
19 Apr, 2022 | 01:32h | UTCNews Release: AI reduces miss rate of precancerous polyps in colorectal cancer screening – Mayo Clinic
Original Study: Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia – Gastroenterology (link to abstract – $ for full-text)
Review | Frontline therapy for advanced hepatocellular carcinoma.
19 Apr, 2022 | 01:23h | UTC
10-year results of a phase 3 RCT: High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer.
19 Apr, 2022 | 01:22h | UTCHigh-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology (link to abstract – $ for full-text)
ASCO Guideline Update: Use of immune checkpoint inhibitor Pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer.
19 Apr, 2022 | 01:18h | UTC
Endocrine therapies for breast and prostate cancers: Essentials for primary care.
19 Apr, 2022 | 01:14h | UTC
Phase 2 RCT: De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer.
18 Apr, 2022 | 09:31h | UTCDe-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Advanced testing for human papillomavirus infection improves prognostic evaluation in cervical cancer.
18 Apr, 2022 | 09:33h | UTCHuman Papillomavirus Infection Determines Prognosis in Cervical Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer— RNA sequencing identified more HPV+ tumors, showed 43% mortality disparity for HPV- tumors – MedPage Today (free registration required)
Cohort Study: Non-O blood type is associated with increased risk of venous thromboembolism in patients with cancer.
14 Apr, 2022 | 08:29h | UTCABO blood group type and risk of venous thromboembolism in patients with cancer – Blood Advances (link to abstract – $ for full-text)
Review: Ethical considerations for Phase I trials in oncology.
14 Apr, 2022 | 08:14h | UTCEthical Considerations for Phase I Trials in Oncology – Journal of Clinical Oncology
Commentary on Twitter
🤔 #JCO #CommentsAndControversies: Wondering or wanting to update your knowledge about #ethics & contemporary cancer #phase1 #ClinicalTrials? Check out this review by @RemNil10 @selin_bicer1 @EthicsdoctorP @KimmelmanJ 👉 https://t.co/yYVq0y3QdU pic.twitter.com/ciQlw1mxcj
— Journal of Clinical Oncology (@JCO_ASCO) April 11, 2022
Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with hematuria.
14 Apr, 2022 | 08:16h | UTCSystematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuriahttps://t.co/zB6CHYKprL@stingrai78 @drimranomar @ahmostafid @soukup_viktor @Phil_Violette pic.twitter.com/Ouv3lFfRpm
— European Urology (@EUplatinum) April 11, 2022
Cohort Study: Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer.
14 Apr, 2022 | 07:59h | UTCCommentary: Men treated for prostate cancer have increased fracture risk, yet few complete DXA screening – HealthImaging
Commentary on Twitter
In this cohort study, osteoporosis screening rates for over 50,000 elderly men with prostate cancer receiving hormonal therapy nationwide were very low; men who were screened were less likely to suffer major fractures in follow-up. https://t.co/RMz1bvEgiA
— JAMA Network Open (@JAMANetworkOpen) April 1, 2022
Review | Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma.
14 Apr, 2022 | 08:03h | UTC
Development and validation of a decision analytical model for posttreatment surveillance for patients with oropharyngeal carcinoma.
14 Apr, 2022 | 07:52h | UTC
Evaluation of information theoretic network meta-analysis to rank first-line anticancer regimens for hormone receptor–positive, ERBB2-negative metastatic breast cancer.
14 Apr, 2022 | 07:48h | UTCInvited Commentary: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor–Positive, ERBB2-Negative Breast Cancer Treatment – JAMA Network Open
Study identifies which treatments are associated with an increased risk of heart disease among women with breast cancer.
13 Apr, 2022 | 10:00h | UTCRisk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Major study links breast cancer treatment with increased risk of cardiovascular disease – Fred Hutch
Commentary on Twitter
Great case-control study in a modern cohort evaluating long-term cardiovascular disease after #breastcancer treatment. HR for heart failure/cardiomyopathy higher for anthracyclines (HR=1.84) and herceptin (HR=2.53) than for #radiotherapy (HR=1.38). #bcsmhttps://t.co/ZEVfbwlepr
— Shane Stecklein, MD, PhD (@shanestecklein) April 8, 2022
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management.
12 Apr, 2022 | 10:02h | UTC
RCT: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.
12 Apr, 2022 | 08:54h | UTCNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer – New England Journal of Medicine
News Release: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer – Johns Hopkins Medicine
Commentary on Twitter
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemo results in longer event-free survival and a greater likelihood of pathological complete response than chemo alone. #AACR22 https://t.co/ILjdRZQ7dJ pic.twitter.com/1JfiUw18R6
— NEJM (@NEJM) April 11, 2022